By Steve Usdin
Contributing Editor

WASHINGTON - The refusal of an FDA advisory panel last Thursday to endorse Cephalon Inc.'s Myotrophin insulin-like growth factor 1 (IGF-1) as a treatment for amyotrophic lateral sclerosis was a major setback for the compound, but it may not have been a terminal event.